Comprehensive gene expression profiles of NK cell neoplasms identify vorinostat as an effective drug candidate

Cancer Letters

Volumn 333, Issue 1, 2013, Pages 47-55

  Karube, Kennosuke ^a   Tsuzuki, Shinobu ^a   Yoshida, Noriaki ^a,b   Arita, Kotaro ^a   Kato, Harumi ^a   Katayama, Miyuki ^a   Ko, Young Hyeh ^c   Ohshima, Koichi ^d   Nakamura, Shigeo ^e   Kinoshita, Tomohiro ^f   Seto, Masao ^a,b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NAGOYA UNIVERSITY HOSPITAL   (Japan)

^f Aichi Cancer ^*  (Japan)

Author keywords

Connectivity map; Jak STAT pathway; Lymphoma; Natural killer; Vorinostat

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; PHENOXYBENZAMINE; PUROMYCIN; STAT3 PROTEIN; TRICHOSTATIN A; VORINOSTAT; WNT PROTEIN; WORTMANNIN;

AGGRESSIVE NK CELL LEUKEMIA; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; HYDROXAMIC ACIDS; JANUS KINASE 3; KILLER CELLS, NATURAL; LYMPHOMA; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTOME;

EID: 84876083367     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.12.022     Document Type: Article

References (48)

1. Chan J.K.C., Quintanilla-Martinez L., Ferry J.A., Peh S.C. Extranodal NK/T-cell lymphoma, nasal type. WHO Classification of Tumours Haematopoietic and Lymphoid Tissues 2009, 285-288. IARC Press, Lyon, France. S.H.C.E. Swerdlow, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman (Eds.).
2. Chan J.K.C., Jaffe E.S., Ralfkiaer E., Ko Y.H. Aggressive NK-cell leukaemia. WHO Classification of Tumours Haematopoietic and Lymphoid Tissues 2009, 276-277. Lyon, France, IARC Press. S.H.C.E. Swerdlow, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman (Eds.).
3. Yamaguchi M., Kita K., Miwa H., et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995, 76:2351-2356.
4. Egashira M., Kawamata N., Sugimoto K., Kaneko T., Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 1999, 93:599-606.
5. Yamaguchi M., Tobinai K., Oguchi M., et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J. Clin. Oncol. 2009, 27:5594-5600.
6. Suzuki R., Suzumiya J., Nakamura S., et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004, 18:763-770.
7. Lee J., Suh C., Park Y.H., et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J. Clin. Oncol. 2006, 24:612-618.
8. Yok-Lam K. The diagnosis and management of extranodal NK/T-cell lymphoma, nasal-type and aggressive NK-cell leukemia. J. Clin. Exp. Hematop. 2011, 51:21-28.
9. Iqbal J., Weisenburger D.D., Chowdhury A., et al. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia 2011, 25:348-358.
10. Huang Y., de Reynies A., de Leval L., et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 2010, 115:1226-1237.
11. Hess G. Temsirolimus for the treatment of mantle cell lymphoma. Expert Rev. Hematol. 2009, 2:631-640.
12. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27:5459-5468.
13. Karube K., Nakagawa M., Tsuzuki S., et al. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood 2011, 118:3195-3204.
14. Iqbal J., Kucuk C., Deleeuw R.J., et al. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 2009, 23:1139-1151.
15. Ng S.B., Yan J., Huang G., et al. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood 2011, 118:4919-4929.
16. Koo G.C., Tan S.Y., Tang T., et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2012, 2:591-597.
17. Lamb J., Crawford E.D., Peck D., et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935.
18. Tsuchiyama J., Yoshino T., Mori M., et al. Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection. Blood 1998, 92:1374-1383.
19. Nagata H., Konno A., Kimura N., et al. Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood 2001, 97:708-713.
20. Gong J.H., Maki G., Klingemann H.G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994, 8:652-658.
21. Robertson M.J., Cochran K.J., Cameron C., Le J.M., Tantravahi R., Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp. Hematol. 1996, 24:406-415.
22. Kagami Y., Nakamura S., Suzuki R., et al. Establishment of an IL-2-dependent cell line derived from 'nasal-type' NK/T-cell lymphoma of CD2+, sCD3-, CD3epsilon+, CD56+ phenotype and associated with the Epstein-Barr virus. Br. J. Haematol. 1998, 103:669-677.
23. Yagita M., Huang C.L., Umehara H., et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 2000, 14:922-930.
24. Zhang Y., Nagata H., Ikeuchi T., et al. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Br. J. Haematol. 2003, 121:805-814.
25. Arima N., Molitor J.A., Smith M.R., Kim J.H., Daitoku Y., Greene W.C. Human T-cell leukemia virus type I Tax induces expression of the Rel-related family of kappa B enhancer-binding proteins: evidence for a pretranslational component of regulation. J. Virol. 1991, 65:6892-6899.
26. Arima N., Arimura K., Tokito Y., et al. HTLV-I Tax protein inhibits apoptosis induction but not G1 arrest by pyrrolidinedithiocarbamate, an anti-oxidant, in adult T cell leukemia cells. Exp. Hematol. 2004, 32:195-201.
27. Subramanian A., Tamayo P., Mootha V.K., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
28. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 1998, 95:14863-14868.
29. Kaszuba-Zwoinska J., Wojcik K., Bereta M., et al. Pulsating electromagnetic field stimulation prevents cell death of puroMYCin treated U937 cell line. J. Physiol. Pharmacol. 2010, 61:201-205.
30. Ikezoe T., Nishioka C., Bandobashi K., et al. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapaMYCin induces growth arrest of adult T-cell leukemia cells. Leuk. Res. 2007, 31:673-682.
31. Kim S.H., Um J.H., Dong-Won B., et al. Potentiation of chemosensitivity in multidrug-resistant human leukemia CEM cells by inhibition of DNA-dependent protein kinase using wortmannin. Leuk. Res. 2000, 24:917-925.
32. De Preter K., De Brouwer S., van Maerken T., et al. Meta-mining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds. Clin. Cancer Res. 2009, 15:3690-3696.
33. Kawamata N., Chen J., Koeffler H.P. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 2007, 110:2667-2673.
34. Izumiyama K., Nakagawa M., Yonezumi M., et al. Stability and subcellular localization of API2-MALT1 chimeric protein involved in t(11;18) (q21;q21) MALT lymphoma. Oncogene 2003, 22:8085-8092.
35. Lipson D., Aumann Y., Ben-Dor A., Linial N., Yakhini Z. Efficient calculation of interval scores for DNA copy number data analysis. J. Comput. Biol. 2006, 13:215-228.
36. Coppo P., Gouilleux-Gruart V., Huang Y., et al. STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma. Leukemia 2009.
37. Khan O., La Thangue N.B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol. 2011, 90:85-94.
38. Shin J.Y., Kim J.O., Lee S.K., Chae H.S., Kang J.H. LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells. BMC Cancer 2010, 10:425.
39. Gires O., Kohlhuber F., Kilger E., et al. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. Embo. J. 1999, 18:3064-3073.
40. Xargay-Torrent S., Lopez-Guerra M., Saborit-Villarroya I., et al. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. Clin. Cancer Res. 2011, 17:3956-3968.
41. Fantin V.R., Loboda A., Paweletz C.P., et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 2008, 68:3785-3794.
42. Watanabe T., Kato H., Kobayashi Y., et al. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci. 2010, 101:196-200.
43. Duvic M., Talpur R., Ni X., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31-39.
44. Zhang C., Richon V., Ni X., Talpur R., Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J. Invest. Dermatol. 2005, 125:1045-1052.
45. Buglio D., Georgakis G.V., Hanabuchi S., et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008, 112:1424-1433.
46. Peart M.J., Smyth G.K., van Laar R.K., et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 2005, 102:3697-3702.
47. Hui K., Ho D.N., Tsang C., Middeldorp J.M., Tsao G.S., Chiang A.K. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma. Int. J. Cancer 2012.
48. Hui K.F., Chiang A.K. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. Int. J. Cancer 2010, 126:2479-2489.